The present invention relates to compositions, particularly liquid compositions, comprising polypeptides having beta-galactosidase activity, methods of making said compositions, and uses of the compositions for making e.g. dairy products. The polypeptides having beta-galactosidase activity are modified by glycation of lysine and/or arginine residues by incubating the enzyme in the presence of reducing sugars, optionally combined with a heat treatment. Thereby, transgalactosylating activity is increased.

The present invention relates to compositions, particularly liquid compositions, comprising polypeptides having beta-galactosidase activity, methods of making said compositions, and uses of the compositions for making e.g. dairy products. The polypeptides having beta-galactosidase activity are modified by glycation of lysine and/or arginine residues by incubating the enzyme in the presence of reducing sugars, optionally combined with a heat treatment. Thereby, transgalactosylating activity is increased.

A spray-dried composition comprising an enzyme which is a β-galactosidase having transgalactosylating activity and a maltodextrin and/or sodium chloride.

The invention relates to carrier complexes and methods for delivering molecules to cells. The carrier complexes comprises a molecule and an aromatic cationic peptide in accordance with the invention. In one embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a carrier complex. In another embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a molecule and an aromatic cationic peptide.

The present invention relates to the use of at least one tetra functional non-ionic amphiphilic block copolymer as a vehicle for capped or uncapped mRNA for intracellular delivery for gene therapy.

The present invention relates to new improved peptide or dimeric peptides exhibiting betagalactosidase enzyme activity as well as improved methods for reducing the lactose content in compositions, such as dairy products.

The disclosure provides gene therapy vectors and methods of use thereof for treating genetic diseases, such as lysosomal storage diseases. For example, the disclosure provides gene therapy vectors and methods for treating GM1 gangliosidosis. The disclosure also provide methods for making the provided gene therapy vectors.

The present invention relates to new improved peptide or dimeric peptides exhibiting betagalactosidase enzyme activity wherein the peptide has a pH optimum at acidic conditions.

A method for producing a secreted β-galactosidase, characterized by integrating a non-secreted β-galactosidase gene derived from a basidiomycetous yeast into Aspergillus oryzae to produce a secreted β-galactosidase, and a method for producing a galactooligosaccharide using a β-galactosidase produced by the method facilitate the production of a galactooligosaccharide.

A method for producing allolactose is provided. Allolactose is produced by bringing cells of a microorganism having beta-galactosidase (BGL) into contact with lactose in the presence of a substance that inhibits hydrolysis of allolactose.